Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Chilton Capital Management LLC Has $49 Million Holdings in Gilead Sciences, Inc. $GILD
05:20am, Tuesday, 27'th Jan 2026
Chilton Capital Management LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 18.4% during the third quarter, according to its most recent 13F filing with the SEC. The institut
Gilead Sciences, Inc. $GILD Shares Sold by AEGON ASSET MANAGEMENT UK Plc
03:34am, Monday, 26'th Jan 2026
AEGON ASSET MANAGEMENT UK Plc decreased its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 3.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC.
First Citizens Bank & Trust Co. Purchases 61,959 Shares of Gilead Sciences, Inc. $GILD
05:24am, Sunday, 25'th Jan 2026
First Citizens Bank and Trust Co. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 589.4% during the undefined quarter, according to the company in its most recent 13F filing w
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
07:01pm, Thursday, 22'nd Jan 2026
Gilead Sciences (GILD) reached $131.14 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
Boston Common Asset Management LLC Has $14.40 Million Holdings in Gilead Sciences, Inc. $GILD
04:56am, Thursday, 22'nd Jan 2026
Boston Common Asset Management LLC grew its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 6.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEY
Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced
01:03pm, Tuesday, 20'th Jan 2026
Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Core HIV business remains stable, while new product launches and acquisitions, notably Li
Wealth Management Associates, Inc. Buys 285 Shares of Gilead Sciences Inc (GILD)
09:08am, Tuesday, 20'th Jan 2026
Summary Wealth Management Associates, Inc. raised its stake in Gilead Sciences Inc (GILD) by 12.39%, purchasing 285 shares to own 2,585 shares valued a
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of “Moderate Buy” by Brokerages
04:58am, Monday, 19'th Jan 2026
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) has received an average rating of "Moderate Buy" from the twenty-eight research firms that are covering the company, MarketBeat reports. Three re
Csenge Advisory Group Has $2.38 Million Stock Holdings in Gilead Sciences, Inc. $GILD
05:56am, Sunday, 18'th Jan 2026
Csenge Advisory Group raised its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 319.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchang
Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)
01:41pm, Friday, 16'th Jan 2026
Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion
Gilead Sciences, Inc. $GILD Shares Sold by Conning Inc.
04:46am, Thursday, 15'th Jan 2026
Conning Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 8.5% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 291,475 shares of the biophar
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Wednesday, 14'th Jan 2026
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
07:00pm, Monday, 12'th Jan 2026
In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading day.
Gilead Sciences: From All-Time Highs To Higher Highs
05:40pm, Monday, 12'th Jan 2026
Gilead has successfully launched Yeztugo, the successor to its blockbuster Biktarvy. Gilead expects Yeztugo sales to reach $100 million in Q4, even though it was only approved by the FDA on June 18 la
